Evidence map›Paper›PMID 23077666›Full record

ArticlePloS one2012

Conditional astroglial Rictor overexpression induces malignant glioma in mice.

Tariq Bashir, Cheri Cloninger, Nicholas Artinian, Lauren Anderson, Andrew Bernath, Brent Holmes, Angelica Benavides-Serrato, Nesrin Sabha, Robert N Nishimura, Abhijit Guha and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. [MicroRNA-152 and microRNA-448 inhibit proliferation of colorectal cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Tariq BashirDepartment of Research and Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California, United States of America.
Cheri Cloninger
Nicholas Artinian
Lauren Anderson
Andrew Bernath
Brent Holmes
Angelica Benavides-Serrato
Nesrin Sabha
Robert N Nishimura
Abhijit Guha
Joseph Gera
VA Greater Los Angeles Healthcare System · USHospital for Sick Children · CASickKids Foundation · CAUniversity of California, Los Angeles · US

Funding

Mechanisms of AKT-dependent sensitivity to rapamycinR01CA109312 · NCI · SEPULVEDA RESEARCH CORPORATION · PI GERA, JOSEPH F · 2005 to 2012
$1.6M
Dysregulation of mTORC2 in gliomasR01CA168700 · NCI · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI GERA, JOSEPH F · 2012 to 2015
$898k
NCI NIH HHS R01 CA109312NCI NIH HHS R01CA109312NCI NIH HHS R01 CA168700
6 · The paper itself

Abstract

backgroundHyperactivation of the mTORC2 signaling pathway has been shown to contribute to the oncogenic properties of gliomas. Moreover, overexpression of the mTORC2 regulatory subunit Rictor has been associated with increased proliferation and invasive character of these tumor cells. METHODOLOGY/PRINCIPAL

findingsTo determine whether Rictor overexpression was sufficient to induce glioma formation in mice, we inserted a Cre-lox-regulated human Rictor transgene into the murine ROSA26 locus. This floxed Rictor strain was crossed with mice expressing the Cre recombinase driven from the glial fibrillary acidic protein (GFAP) promoter whose expression is limited to the glial cell compartment. Double transgenic GFAP-Cre/Rictor(loxP/loxP) mice developed multifocal infiltrating glioma containing elevated mTORC2 activity and typically involved the subventricular zone (SVZ) and lateral ventricle. Analysis of Rictor-dependent signaling in these tumors demonstrated that in addition to elevated mTORC2 activity, an mTORC2-independent marker of cortical actin network function, was also elevated. Upon histological examination of the neoplasms, many displayed oligodendroglioma-like phenotypes and expressed markers associated with oligodendroglial lineage tumors. To determine whether upstream oncogenic EGFRvIII signaling would alter tumor phenotypes observed in the GFAP-Cre/Rictor(loxP/loxP) mice, transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice were generated. These mice developed mixed astrocytic-oligodendroglial tumors, however glioma formation was accelerated and correlated with increased mTORC2 activity. Additionally, the subventricular zone within the GFAP-Cre/Rictor(loxP/loxP) mouse brain was markedly expanded, and a further proliferation within this compartment of the brain was observed in transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice. CONCLUSION/SIGNIFICANCE: These data collectively establish Rictor as a novel oncoprotein and support the role of dysregulated Rictor expression in gliomagenesis via mTOR-dependent and mTOR-independent mechanisms. Furthermore, oncogenic EGFRvIII signaling appears to potentiate the in vivo proliferative capacity of GFAP-Cre/Rictor(loxP/loxP) gliomas.

Indexed as

Carrier ProteinsGliomaMultiprotein ComplexesProteinsTOR Serine-Threonine KinasesAnimalsAstrocytesCell ProliferationErbB ReceptorsGene Expression Regulation, NeoplasticHumansMechanistic Target of Rapamycin Complex 2MiceMice, TransgenicRapamycin-Insensitive Companion of mTOR ProteinRNA, UntranslatedCarrier Proteinsepidermal growth factor receptor VIIIErbB ReceptorsGt(ROSA)26Sor non-coding RNA, mouseMechanistic Target of Rapamycin Complex 2Multiprotein ComplexesProteinsRapamycin-Insensitive Companion of mTOR Proteinrictor protein, mouseRNA, UntranslatedTOR Serine-Threonine Kinases

Identifiers

PMID23077666
PMCPMC3471885
OpenAlexW2046393628

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.